310 related articles for article (PubMed ID: 25605842)
1. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
Mitsiades CS
J Clin Oncol; 2015 Mar; 33(7):782-5. PubMed ID: 25605842
[No Abstract] [Full Text] [Related]
2. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
Colland F
IDrugs; 2006 Mar; 9(3):179-81. PubMed ID: 16523381
[No Abstract] [Full Text] [Related]
4. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Cvek B; Dvorak Z
Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
[TBL] [Abstract][Full Text] [Related]
5. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
[TBL] [Abstract][Full Text] [Related]
7. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
8. An historic perspective of proteasome inhibition.
Esseltine DL; Mulligan G
Semin Hematol; 2012 Jul; 49(3):196-206. PubMed ID: 22726542
[TBL] [Abstract][Full Text] [Related]
9. Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells.
Rausch JL; Ali AA; Lee DM; Gebreyohannes YK; Mehalek KR; Agha A; Patil SS; Tolstov Y; Wellens J; Dhillon HS; Makielski KR; Debiec-Rychter M; Schöffski P; Wozniak A; Duensing A
Sci Rep; 2020 Mar; 10(1):5178. PubMed ID: 32198455
[TBL] [Abstract][Full Text] [Related]
10. Clinical and marketed proteasome inhibitors for cancer treatment.
Zhang J; Wu P; Hu Y
Curr Med Chem; 2013; 20(20):2537-51. PubMed ID: 23531219
[TBL] [Abstract][Full Text] [Related]
11. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
12. The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
Yerlikaya A; Kanbur E; Stanley BA; Tümer E
Anticancer Agents Med Chem; 2021; 21(1):20-32. PubMed ID: 32781973
[TBL] [Abstract][Full Text] [Related]
13. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
15. The potential of proteasome inhibitors in cancer therapy.
Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
17. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells.
Dasgupta S; Castro LM; Dulman R; Yang C; Schmidt M; Ferro ES; Fricker LD
PLoS One; 2014; 9(7):e103604. PubMed ID: 25079948
[TBL] [Abstract][Full Text] [Related]
19. When ubiquitin meets NF-κB: a trove for anti-cancer drug development.
Wu ZH; Shi Y
Curr Pharm Des; 2013; 19(18):3263-75. PubMed ID: 23151140
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
